LINCOCIN INJECTION 300 mg/ml

Land: Singapur

Sprache: Englisch

Quelle: HSA (Health Sciences Authority)

Wirkstoff:

LINCOMYCIN HCl EQV LINCOMYCIN

Verfügbar ab:

PFIZER PRIVATE LIMITED

ATC-Code:

J01FF02

Dosierung:

300 mg/ml

Darreichungsform:

INJECTION

Verabreichungsweg:

INTRAVENOUS, INTRAMUSCULAR

Verschreibungstyp:

Prescription Only

Hergestellt von:

PHARMACIA & UPJOHN CO

Berechtigungsdatum:

1988-06-08

Gebrauchsinformation

. 

1

LINCOCIN
®

STERILE SOLUTION 
LINCOMYCIN HYDROCHLORIDE INJECTION, USP 

To reduce the development of drug-resistant bacteria and maintain
the effectiveness of 
LINCOCIN and other antibacterial drugs, LINCOCIN should be used
only to treat or 
prevent infections that are proven or strongly suspected
to be caused by bacteria. 

WARNING 
PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH NEARLY ALL
ANTIBACTERIAL AGENTS, 
INCLUDING LINCOMYCIN, AND MAY RANGE IN SEVERITY FROM MILD TO
LIFE-THREATENING. 
THEREFORE, IT IS IMPORTANT TO CONSIDER THIS DIAGNOSIS IN PATIENTS
WHO PRESENT WITH 
DIARRHEA SUBSEQUENT TO THE ADMINISTRATION OF ANTIBACTERIAL
AGENTS. 

Because lincomycin therapy has been associated with
severe colitis which may end 
fatally, it should be reserved for serious infections where less
toxic antimicrobial agents 
are inappropriate, as described in the INDICATIONS AND
USAGE section. It should 
not be used in patients with non-bacterial infections such as most
upper respiratory tract 
infections. 

Treatment with antibacterial agents alters the normal
flora of the colon and may permit 
overgrowth of clostridia. Studies indicate that a toxin produced
by _Clostridium difficile _is 
one primary cause of “antibiotic-associated colitis”. 

After the diagnosis of pseudomembranous colitis has been established,
therapeutic 
measures should be initiated. Mild cases of pseudomembranous colitis
usually respond to 
drug discontinuation alone. In moderate to severe cases,
consideration should be given to 
management with fluids and electrolytes, protein supplementation,
and treatment with an 
antibacterial drug clinically effective against _C.
difficile _colitis. 
_ _
_Clostridium
difficile _associated diarrhea (CDAD) has been reported with use of nearly all 
antibacterial agents, including lincomycin, and may range in
severity from mild diarrhea to fatal 
colitis. Treatment wi